Piper Sandler analyst Yasmeen Rahimi downgraded Design Therapeutics to Neutral from Overweight with a price target of $6, down from $42, given that the company is going through a strategic process to prioritize long-term growth. The firm still believes in Design’s GeneTac platform and says DT-216 “looks promising,” but given that Design is working on a new formulation that allows for higher dosing and topline data is not expected until the second half of 2025, a lack of clinical data “will result in limited news flow, and thus limit the number of stock moving events,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DSGN: